Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 12077595 Single domain antibodies that bind to CD137

Patent 12077595 was granted and assigned to Crescendo Biologics on September, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Crescendo Biologics
Crescendo Biologics
0
Date Filed
November 13, 2018
0
Date of Patent
September 3, 2024
0
Patent Applicant
Crescendo Biologics
Crescendo Biologics
0
Patent Application Number
16763059
0
Patent Citations
‌
US Patent 10975161 Molecules that bind prostate specific membrane antigen (PSMA)
0
‌
US Patent 11236174 Therapeutic molecules
0
‌
US Patent 11591398 Single domain antibodies to programmed cell death protein 1 (PD-1)
0
‌
US Patent 11312771 Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
0
‌
US Patent 7728114 Anti-CD3 antibodies and methods of use thereof
0
‌
US Patent 7851598 Receptor modulators
0
‌
US Patent 9872852 Compounds useful as immunomodulators
0
‌
US Patent 10202458 IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
0
‌
US Patent 10323090 PD1 and/or LAG3 binders
0
Patent Inventor Names
James Legg
0
Verena Brucklacher-Waldert
0
Christine Rossant
0
Carolyn Edwards
0
Jayesh Majithiya
0
Brian McGuinness
0
Yumin Teng
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12077595
0
Patent Primary Examiner
‌
Zachary S Skelding
0

Find more entities like US Patent 12077595 Single domain antibodies that bind to CD137

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.